Clinical trials: Cardiovascular Disease Acute
Acute Ischemic Stroke
Reperfuse Ischemic Vessels With Endovascular Recanalization Device in JAPAN (RIVER JAPAN)
The main objective of this study is to document that the thrombectomy catheter (Rev-01) is effective and safe when used for revascularization in subjects with acute ischemic stroke within 8 hours of symptom onset who are…
- Trial name
- NCT01895634
- Testing
- Rev-01
- Where
- Japan
- Volunteers
- 49 people
- Sponsor
- Johnson & Johnson K.K. Medical Company
Myocardial Infarction
Acute Myocardial Infarction With HyperOxemic Therapy II (AMIHOT II)
To determine whether or not HyperOxemic therapy rendered to patients (that meet the study inclusion criteria) with anterior acute myocardial infarction < 6 hours from symptom onset to reperfusion, results in a significant…
- Trial name
- AMIHOT II (NCT00175058)
- Testing
- AO Therapy (aqueous oxygen)
- Where
- United States
- Volunteers
- 317 people
- Sponsor
- TherOx
Atrial Fibrillation
Performance of QDOT Micro™ Catheter With nGEN Generator for Patients With AFIB.
This workflow study will further evaluate the acute performance and safety of the QDOT MICRO™ catheter in a clinical setting used in combination with nGEN Generator. Subjects will be followed for 7 days post procedure.
- Trial name
- NCT04545619
- Testing
- QDOT MICRO System
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- Biosense Webster, Inc.
Myocardial Infarction
Firibastat or Ramipril After Acute Myocardial Infarction for Prevention of Left Ventricular Dysfunction
This is a multicenter, randomized, double-blind, active-controlled, dose-titrating phase 2 study to evaluate the safety and efficacy of firibastat administered orally BID (2 daily doses) versus ramipril administered orally BID…
- Trial name
- QUORUM (NCT03715998)
- Testing
- Ramipril, Firibastat
- Where
- 7 sites in France, Germany and 5 more
- Volunteers
- 295 people
- Sponsor
- Quantum Genomics SA
Acute Coronary Syndrome (ACS)
Lp(a) Lowering Study of Pelacarsen (TQJ230) in Patients in the US With Elevated Lp(a) and Recent ACS (STEMI/NSTEMI) - Lp(a)FRONTIERS PEARL
CTQJ230A1US13 is a randomized, double-blind, placebo-controlled, multicenter phase IIIb study designed to evaluate the efficacy, safety, tolerability, and coronary plaque effects of early pelacarsen (TQJ230) initiation in…
- Trial name
- NCT07625306
- Testing
- Pelacarsen
- Sponsor
- Novartis Pharmaceuticals
Ischemic Stroke
Efficacy and Safety of SP-8203 in Patients With Ischemic Stroke Requiring rtPA
This clinical trial is designed to evaluate the efficacy and safety of the combination therapy of SP-8203 (Otaplimastat) and recombinant tissue Plasminogen Activator (rtPA) standard of care.
- Trial name
- SP-8203-2002 (NCT04479449)
- Testing
- SP-8203
- Where
- South Korea
- Volunteers
- 178 people
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Tricuspid Regurgitation Functional
Acute Safety and Efficacy of the Pivot Bridge System for Functional Tricuspid Regurgitation
The purpose of this clinical trial is as follows. To assess the safety of the investigational medical device "Pivot Bridge" in participants aged 18 years or older with massive or greater functinal tricuspid regurgitation (TR) who…
- Trial name
- Pivot TR (NCT07385625)
- Testing
- Pivot Bridge
- Where
- 4 sites in South Korea
- Volunteers
- 20 people
- Sponsor
- Tau-MEDICAL Co., Ltd.
ST Elevation Myocardial Infarction
MGuard™ Prime Stent System Clinical Trial in Patients With Acute ST Elevation Myocardial Infarction
To evaluate the safety and efficacy of the MGuard™ Prime stent in the treatment of blocked arteries in coronary arteries in patients undergoing a stenting procedure due to having a heart attack.
- Trial name
- MASTER-II (NCT01869738)
- Testing
- MGuard Prime, (BMS/DES)
- Where
- 56 sites in United States, Belgium and 10 more
- Volunteers
- 310 people
- Sponsor
- InspireMD
Acute Ischemic Stroke
A Feasibility Study for the DAISe EZ Thrombectomy Device - Pacific
The study is a prospective, multi-center, single arm, feasibility study that will enroll a maximum of 20 subjects. A maximum of 5 investigational centers in Australia will participate.
- Trial name
- NCT06042335
- Testing
- DAISe EZ
- Volunteers
- 20 people
- Sponsor
- MIVI Neuroscience, Inc.
Intracerebral Hemorrhage
Safety of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke
This study will determine if NXY-059 is safe in patients with an acute stroke caused by bleeding in the central nervous system. The primary objective was to assess the safety and tolerability of NXY-059 compared to placebo.
- Trial name
- NCT00075959
- Testing
- NXY-059
- Where
- 64 sites in United States
- Volunteers
- 600 people
- Sponsor
- AstraZeneca
Pulmonary Embolism
Selective Pulmonary-artery Intervention to Reduce Acute Right-heart tEnsion-I
This study study is a prospective, single-arm, multicenter study to evaluate the safety and effectiveness of the Vertex Pulmonary Embolectomy System in participants presenting with clinical signs and symptoms of pulmonary…
- Trial name
- SPIRARE I (NCT06571760)
- Testing
- Vertex Pulmonary Embolectomy System
- Where
- 2 sites in Austria, Poland
- Volunteers
- 10 people
- Sponsor
- Neptune Medical
Acute Ischemic Stroke AIS
The STem Cell-derived Extracellular Vesicle Therapy In Acute Ischemic Stroke (STEVIA)
This is a multicenter open-label, single-arm, dose escalation phase I clinical trial to evaluate the safety and tolerability of SNE-101 in patients with acute ischemic stroke
- Trial name
- STEVIA (NCT06995625)
- Testing
- SNE-101
- Where
- 3 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- S&Ebio Co. Ltd.
Ischemic Stroke
The Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke
The study investigated the clinical efficacy and safety of a 10-day course of therapy with daily intravenous administration of 30mL Cerebrolysin based on a comparison with Placebo in patients with acute ischemic stroke.
- Trial name
- CASTA (NCT00868283)
- Testing
- Cerebrolysin, 0.9% Saline Solution
- Where
- 49 sites in China, Hong Kong and 1 more
- Volunteers
- 1,071 people
- Sponsor
- Ever Neuro Pharma GmbH
Stable Angina, Unstable Angina
Safety and Effectiveness Evaluation of COBRA PzF Coronary Stent System: A Post Marketing Observational Registry
A multi-center, prospective, consecutive enrolled, observational registry. The population being studied includes all patients undergoing treatment of "de novo" lesions in native coronary vessels, saphenous vein graft and/or…
- Conditions
- Stable Angina, Unstable Angina, ACS - Acute Coronary Syndrome, STEMI
- Trial name
- eCOBRA (NCT03103620)
- Testing
- COBRA PzF Coronary Stent System
- Where
- 18 sites in France
- Volunteers
- 1,027 people
- Sponsor
- CeloNova BioSciences, Inc.
Pulmonary Embolism
Novel α2-Antiplasmin Inactivation for Lysis of Intravascular Thrombi (NAIL-IT) Trial
Phase II trial of TS23
- Trial name
- NAIL-IT (NCT05408546)
- Testing
- TS23
- Where
- 13 sites in United States
- Volunteers
- 64 people
- Sponsor
- Translational Sciences, Inc.
Cerebral Stroke
Treatment With AX200 for Acute Ischemic Stroke
The AXIS study is a randomized, double-blind, placebo-controlled, dose-escalating phase IIa trial to investigate treatment with AX200 (granulocyte-colony stimulating factor; G-CSF) for acute ischemic stroke.
- Trial name
- NCT00132470
- Testing
- AX200 (G-CSF)
- Where
- 2 sites in Germany
- Volunteers
- 42 people
- Sponsor
- Axaron Bioscience AG
Acute Coronary Syndromes
An Epidemiological Study of Acute Coronary Syndromes in The Greek Population. The TARGET Study
This is a multicenter, 2-phase observational study of acute coronary syndromes (ACS) in Greece, designed to provide real world data on the risk factors of patients presenting to a hospital emergency department with an index…
- Trial name
- TARGET (NCT01061086)
- Where
- 11 sites in Greece
- Volunteers
- 418 people
- Sponsor
- AstraZeneca
Heart Failure
Safety, Pharmacokinetic and Pharmacodynamic Study of COR-1, an Anti-ß1 Receptor Antibody Cyclopeptide
Primary Trial objectives: To evaluate the pharmacokinetics and -dynamics of five strengths of COR-1 (10, 40, 80, 160, 240 mg) in 50 healthy, male volunteers after single intravenous administration (8 subjects on verum per dose…
- Trial name
- COR-1-01 (NCT01043146)
- Testing
- COR-1
- Where
- Germany
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Corimmun GmbH
Diabetic Foot Ulcer, Dehiscence of Amputation Stump
Kerecis Omega3 Wound Plus SOC vs. SOC Alone in Treating Severe Diabetic Foot Ulcers and Forefoot Amputations
This is a prospective, multi-national, multi-centre, randomized, non-blinded (photo evaluation is blinded), controlled clinical investigation in patients suffering from diabetic wounds reaching to tendon, bone, or joint.
- Conditions
- Diabetic Foot Ulcer, Dehiscence of Amputation Stump, Amputation
- Trial name
- Odinn (NCT04257370)
- Testing
- Kerecis™ Omega3 Wound, Standard of care
- Where
- France
- Volunteers
- 260 people
- Sponsor
- Kerecis Ltd.
Aortic Dissection
Zenith® Dissection Clinical Trial
The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of acute, complicate Type B aortic dissection.
- Trial name
- NCT01568320
- Testing
- Endovascular Treatment (Zenith)
- Where
- 24 sites in United States, Japan
- Volunteers
- 73 people
- Sponsor
- Cook Research Incorporated
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.